BioNTech SE (VIE:BNTX)

Market Cap	23.50B
Revenue (ttm)	3.15B
Net Income (ttm)	-571.60M
Shares Out	n/a
EPS (ttm)	-2.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	515
Open	91.65
Previous Close	92.15
Day's Range	91.65 - 93.20
52-Week Range	72.40 - 121.00
Beta	n/a
RSI	73.75
Earnings Date	Mar 10, 2026

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 6,772
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: BNTX